Cargando…
IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer
BACKGROUND: Interleukin-27 signaling is mediated by the JAK-STAT pathway via activation of STAT1 and STAT3, which have tumor suppressive and oncogenic activities, respectively. Epithelial–mesenchymal transition (EMT) and angiogenesis are key processes in carcinogenesis. Although IL-27 has been shown...
Autores principales: | Kachroo, Puja, Lee, Mi-Heon, Zhang, Ling, Baratelli, Felicita, Lee, Gina, Srivastava, Minu K, Wang, Gerald, Walser, Tonya C, Krysan, Kostyantyn, Sharma, Sherven, Dubinett, Steven M, Lee, Jay M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906956/ https://www.ncbi.nlm.nih.gov/pubmed/24274066 http://dx.doi.org/10.1186/1756-9966-32-97 |
Ejemplares similares
-
Increased PD-L1 expression in KRAS mutated premalignant human bronchial epithelial cells is enhanced by LKB1 loss and mediated by ERK activation
por: Lee, Mi-Heon, et al.
Publicado: (2015) -
Novel CCL21-Vault Nanocapsule Intratumoral Delivery Inhibits Lung Cancer Growth
por: Kar, Upendra K., et al.
Publicado: (2011) -
PD-L1 expression correlates with immune response in a Phase I trial of CCL21 gene modified dendritic cell therapy in lung cancer
por: Lee, Jay M, et al.
Publicado: (2014) -
Targeting MDSCs enhance therapeutic vaccination responses against lung cancer
por: Srivastava, Minu K., et al.
Publicado: (2012) -
Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in Non-Small Cell Lung Cancer
por: Baratelli, Felicita, et al.
Publicado: (2008)